RobertMcWilliamsMD

Oncology • Rochester, MN

Gastrointestinal Cancer, Hematologic Oncology, Melanoma

Professor of Oncology

Join to view full profile

Dr. McWilliams is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McWilliams' full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2001 - 2005
Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 2000
Georgetown University School of MedicineClass of 1997

Certifications & Licensure

IA State Medical License 2012 - 2026
ID State Medical License 2012 - 2026
IL State Medical License 2012 - 2026
MT State Medical License 2012 - 2026
NY State Medical License 2012 - 2026
MI State Medical License 2012 - 2025
MN State Medical License 2001 - 2025
ND State Medical License 2012 - 2025
SD State Medical License Active through 2025
TX State Medical License 2015 - 2025
WI State Medical License 2013 - 2025
KY State Medical License 2012 - 2020
MO State Medical License 2012 - 2020
NH State Medical License 2012 - 2020
MD State Medical License 2000 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2006 Oct 01
Completed
Phase 2
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 1
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma Start of enrollment: 2013 Apr 01
Completed
Phase 1
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Start of enrollment: 2016 Jan 01
Completed
Early Phase 1
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 2
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer Start of enrollment: 2020 Dec 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane
Melanoma Research. 2024-12-01
Reducing Cancer Drug Cost: 3-Year Analysis of Automated Dose Rounding in Electronic Health Records.
Vishal S Shah, Clayton Irvine, Robert R McWilliams, Parminder Singh, Scott A Soefje
JCO Oncology Practice. 2024-08-05
KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis.
Ashley N Sigafoos, Ezequiel J Tolosa, Ryan M Carr, Maite G Fernandez-Barrena, Luciana L Almada
Cancer Research Communications. 2024-07-01

Journal Articles

Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
Pashtoon M Kasi, Robert R McWilliams, JAMA
Female Chromosome X Mosaicism Is Age-Related and Preferentially Affects the Inactivated X Chromosome
Chu Chen, J Michael Gaziano, Robert C Kurtz, Anthony M Magliocco, Amy Hutchinson, Robert R McWilliams, Nature

Press Mentions

Palliative Care for Cancer PatientsNovember 22nd, 2024
People with Pancreatic Cancer Are Living Longer, Thanks to Improved ApproachesNovember 30th, 2022
The Topic of CancerJuly 1st, 2022
Join now to see all